Kala Pharmaceuticals Inc (KALA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kala Pharmaceuticals Inc (KALA) has a cash flow conversion efficiency ratio of -0.651x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.56 Million) by net assets ($7.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Kala Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.
Kala Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Kala Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check KALA cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Kala Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kala Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Coral India Finance & Housing Limited
NSE:CORALFINAC
|
0.048x |
|
RENALYTIX PLC LS-0025
F:2O9
|
N/A |
|
Havsfrun Investment AB (publ)
ST:HAV-B
|
0.008x |
|
Denali Capital Acquisition Corp. Class A Ordinary Shares
NASDAQ:DECA
|
0.008x |
|
Nusatama Berkah Tbk PT
JK:NTBK
|
-0.177x |
|
Buxton Resources Ltd
AU:BUX
|
-0.863x |
|
Intrasoft Technologies Limited
NSE:ISFT
|
0.038x |
|
Eratex Djaja Tbk
JK:ERTX
|
0.189x |
Annual Cash Flow Conversion Efficiency for Kala Pharmaceuticals Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Kala Pharmaceuticals Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Kala Pharmaceuticals Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.00 Million | $-31.99 Million | -4.573x | -91.92% |
| 2024-12-31 | $12.33 Million | $-29.38 Million | -2.383x | +35.98% |
| 2023-12-31 | $7.50 Million | $-27.93 Million | -3.722x | +10.51% |
| 2022-12-31 | $18.97 Million | $-78.91 Million | -4.159x | +35.43% |
| 2021-12-31 | $16.80 Million | $-108.23 Million | -6.441x | -610.16% |
| 2020-12-31 | $100.00 Million | $-90.69 Million | -0.907x | +70.96% |
| 2019-12-31 | $29.69 Million | $-92.72 Million | -3.123x | -505.76% |
| 2018-12-31 | $104.99 Million | $-54.12 Million | -0.516x | -35.58% |
| 2017-12-31 | $89.68 Million | $-34.10 Million | -0.380x | -222.02% |
| 2016-12-31 | $-87.76 Million | $-27.35 Million | 0.312x | -88.04% |
| 2015-12-31 | $-5.79 Million | $-15.09 Million | 2.605x | +155.31% |
| 2014-12-31 | $3.26 Million | $-15.36 Million | -4.709x | +91.23% |
| 2013-12-31 | $202.00K | $-10.84 Million | -53.673x | -- |
About Kala Pharmaceuticals Inc
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more